secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001437749-24-007543
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene posts FY2023 net loss $49.5M; FDA discussions for CNM-Au8 accelerated approval ongoing
--------------------------------------------------------------------------------

- Net loss $49.5M ($0.47/share) vs $29.9M ($0.46/share) in FY2022; cash $35.0M, expected to fund ops into Q4 2024.
- R&D expenses $26.7M (down from $31.9M); G&A $14.4M (down from $16.9M).
- FDA Q4 2023 meeting: initial NfL biomarker data insufficient for accelerated approval; planning supplemental data submission in 2024, potential NDA.
- HEALEY ALS OLE: CNM-Au8 reduced plasma NfL at 76 wks (p=0.023) and 60% decreased risk of all-cause mortality (>18 months, p=0.0167).
- EAP survival: 68% and 57% reduced mortality risk vs historical controls (p=0.0001); MS trial showed vision and cognition improvements through 35 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924007543/0001437749-24-007543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924007543/clnn20231022_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-007543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer